Dyne Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($2.94) Per Share (NASDAQ:DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Equities research analysts at Chardan Capital issued their FY2025 earnings estimates for Dyne Therapeutics in a note issued to investors on Monday, May 6th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings of ($2.94) per share for the year. Chardan Capital has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.27) per share.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.17).

Several other research firms have also recently commented on DYN. Stifel Nicolaus upped their price target on Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Piper Sandler raised their price objective on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 3rd. Morgan Stanley started coverage on shares of Dyne Therapeutics in a research note on Tuesday, April 30th. They set an “overweight” rating and a $40.00 price target on the stock. Finally, Oppenheimer restated an “outperform” rating and set a $47.00 target price on shares of Dyne Therapeutics in a research report on Monday. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $37.75.

Dyne Therapeutics Trading Up 0.2 %

Shares of DYN opened at $25.69 on Wednesday. The company’s 50 day simple moving average is $26.49 and its 200-day simple moving average is $18.88. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $30.27. The firm has a market cap of $2.24 billion, a PE ratio of -6.47 and a beta of 1.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wetzel Investment Advisors Inc. acquired a new position in Dyne Therapeutics during the 1st quarter worth approximately $28,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Dyne Therapeutics by 58.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after buying an additional 3,092 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Dyne Therapeutics by 95.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock worth $83,000 after buying an additional 4,552 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Dyne Therapeutics by 355.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after buying an additional 5,541 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Dyne Therapeutics by 10.7% during the third quarter. Principal Financial Group Inc. now owns 15,229 shares of the company’s stock worth $136,000 after acquiring an additional 1,476 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In other news, COO Susanna Gatti High sold 2,292 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $25.70, for a total value of $58,904.40. Following the completion of the transaction, the chief operating officer now owns 156,800 shares of the company’s stock, valued at $4,029,760. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, COO Susanna Gatti High sold 2,292 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $25.70, for a total transaction of $58,904.40. Following the transaction, the chief operating officer now directly owns 156,800 shares in the company, valued at approximately $4,029,760. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Wildon Farwell sold 1,585 shares of Dyne Therapeutics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the transaction, the insider now owns 151,590 shares in the company, valued at approximately $3,895,863. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,875,432 shares of company stock valued at $44,368,530. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.